251 related articles for article (PubMed ID: 33962065)
1. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
[TBL] [Abstract][Full Text] [Related]
2. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.
Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G
Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
6. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
7. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
Hakim A; Braun H; Thornton D; Strymish J
Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of dalbavancin against staphylococci isolated in Istanbul, Turkey.
Aktas G; Derbentli S
Chemotherapy; 2010; 56(6):444-7. PubMed ID: 21088395
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.
Matesanz M; Poza A; Iñurrieta A; Fernández-Diaz E; Arroyo M; Domínguez I; Candel FJ
Rev Esp Quimioter; 2021 Aug; 34(4):396-399. PubMed ID: 33956412
[No Abstract] [Full Text] [Related]
13. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
15. Dalbavancin in Gram-positive periprosthetic joint infections.
Simon S; Frank BJH; Hartmann S; Hinterhuber L; Reitsamer M; Aichmair A; Dominkus M; Söderquist B; Hofstaetter JG
J Antimicrob Chemother; 2022 Jul; 77(8):2274-2277. PubMed ID: 35678452
[TBL] [Abstract][Full Text] [Related]
16. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
Kussmann M; Obermueller M; Berndl F; Reischer V; Veletzky L; Burgmann H; Poeppl W
Sci Rep; 2018 Jun; 8(1):9661. PubMed ID: 29941909
[TBL] [Abstract][Full Text] [Related]
19. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
20. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
Koeth LM; DiFranco-Fisher JM; McCurdy S
J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]